TUCSON, Ariz.--(BUSINESS WIRE)--High Throughput Genomics, Inc., (HTG) a provider of novel microplate-based gene expression assay technology and services for the pharmaceutical and life sciences industries, today announced it has closed the first tranche of its Series C financing. The round was led by Merck Capital Ventures and included existing investors Solstice Capital and Valley Ventures as well as first time investor Arcturus Capital. HTG will utilize the funding to expand research and product development efforts in the areas of molecular diagnostics and proteomics as well as build out the commercialization team.
